london euretina
retina race

One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients

Session Details

Session Title: AMD III

Session Date/Time: Sunday 20/09/2015 | 11:00-13:00

Paper Time: 12:52

Venue: Athena

First Author: : Y.Oshima JAPAN

Co Author(s): :    S. Shiose   M. Yasuda   K. Kano   S. Nakao   S. Yoshida   T. Ishibashi

Abstract Details

PURPOSE:To evaluate the one-year outcome of intravitreal injection of aflibercept (IVA) in patients with polypoidal choroidal vasculopathy (PCV) in Japanese patients.

Setting:

This study was carried out retrospectively in Kyushu University Hospital, Fukuoka, Japan.

Methods:

Fourteen eyes with polypoidal choroidal vasculopathy (PCV) in treatment naïve were treated with aflibercept studied retrospectively. Outcomes were determined at least one year after the first aflibercept injection and included mean change of best-corrected visual acuity (BCVA) and mean change in central foveal thickness.

Results:

Mean Log MAR BCVA of baseline was 0.32. The BCVA was significantly improved to 0.2 Log MAR after one-year aflibercept treatment (p=0.002). The average central foveal thickness improved significantly from 312.8μm to 234.4μm (p=0.0002). Complete regression rate of polypoidal lesions were 60% after three months treatment, and 70% after one-year treatment. The mean numbers of aflibercept injections were 6.1 times during first year treatment.

Conclusions:

IVA is well tolerated in eyes with Japanese PCV patients. One-year outcomes of aflibercept treatment for Japanese patients with PCV resulted in stabilization of visual acuity accompanied by anatomical improvement. IVA monotherapy is effective for PCV patients with complete regression of polypoidal lesion.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy